These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29521949)

  • 1. Is 18F-Fluorodeoxyglucose the Tracer of Choice for Functional Imaging of Neuroendocrine Tumors Grade 3? A Case Report.
    Lorusso M; Inzani F; Castaldi P; Menghi R; Schinzari G; Rindi G; Rufini V
    Pancreas; 2018 Apr; 47(4):e20-e22. PubMed ID: 29521949
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatocellular carcinoma and gastroenteropancreatic neuroendocrine tumors: potential role of other positron emission tomography radiotracers.
    Jadvar H
    Semin Nucl Med; 2012 Jul; 42(4):247-54. PubMed ID: 22681673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of Radio-Guided Surgery with ⁶⁸Gallium-DOTATATE in Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumors.
    Sadowski SM; Millo C; Neychev V; Aufforth R; Keutgen X; Glanville J; Alimchandani M; Nilubol N; Herscovitch P; Quezado M; Kebebew E
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S676-82. PubMed ID: 26350374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
    Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
    Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of 18F-fluorodeoxyglucose PET in the study of neuroendocrine tumors.
    Panagiotidis E; Bomanji J
    PET Clin; 2014 Jan; 9(1):43-55. PubMed ID: 25029933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modifying the Poor Prognosis Associated with 18F-FDG-Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT).
    Hofman MS; Michael M; Kashyap R; Hicks RJ
    J Nucl Med; 2015 Jun; 56(6):968-9. PubMed ID: 25814516
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply: Modifying the Poor Prognosis Associated with 18F-FDG-Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT).
    Garin E; Edeline J
    J Nucl Med; 2015 Jun; 56(6):969. PubMed ID: 25908828
    [No Abstract]   [Full Text] [Related]  

  • 8. An Incidental Uptake of 18F-Choline at PET/CT in Gastric Neuroendocrine Tumor.
    Evangelista L; Cassarino G; Capobianco D; Povolato M; Battista S; Rensi M
    Clin Nucl Med; 2021 Apr; 46(4):e238-e239. PubMed ID: 33031248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FLT and 18F-FDG positron emission tomography for the imaging of advanced well-differentiated gastro-entero-pancreatic endocrine tumours.
    Giammarile F; Billotey C; Lombard-Bohas C; Le Bars D; Bournaud C; Masson S; Walter T; Houzard C; Scoazec JY; Hervieu V; Vuillez JP; Cornu C; Janier M; Borson-Chazot F
    Nucl Med Commun; 2011 Feb; 32(2):91-7. PubMed ID: 21076344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffuse Bone Metastases in Pancreatic Neuroendocrine Tumor Shown on Octreoscan.
    Adkins J; Lu Y
    Clin Nucl Med; 2019 Mar; 44(3):257-258. PubMed ID: 30624276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can PET/CT guide the personalized treatment of patients with gastroenteropancreatic neuroendocrine neoplasms?
    Schillaci O
    J Nucl Med; 2014 Nov; 55(11):1757-8. PubMed ID: 25342386
    [No Abstract]   [Full Text] [Related]  

  • 12. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
    Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I
    J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 99mTc-tektrotyd SPECT/MRI in the diagnosis of a gastroenteropancreatic neuroendocrine tumor.
    Zandieh S; Gambini JP; Haller J; Rodrigues M
    Clin Nucl Med; 2012 Apr; 37(4):e84-5. PubMed ID: 22391730
    [No Abstract]   [Full Text] [Related]  

  • 14. Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate?
    Ezziddin S; Lohmar J; Yong-Hing CJ; Sabet A; Ahmadzadehfar H; Kukuk G; Biersack HJ; Guhlke S; Reichmann K
    Clin Nucl Med; 2012 Jun; 37(6):e141-7. PubMed ID: 22614212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lutetium lu 177 dotatate (Lutathera) for gastroenteropancreatic neuroendocrine tumors.
    Med Lett Drugs Ther; 2018 Sep; 60(1555):e152-e153. PubMed ID: 30383735
    [No Abstract]   [Full Text] [Related]  

  • 16. False-positive findings on 6-[18F]fluor-l-3,4-dihydroxyphenylalanine PET (
    Berends AMA; Kerstens MN; Bolt JW; Links TP; Korpershoek E; de Krijger RR; Walenkamp AME; Noordzij W; van Etten B; Kats-Ugurlu G; Brouwers AH; van der Horst-Schrivers ANA
    Eur J Endocrinol; 2018 Aug; 179(2):125-133. PubMed ID: 29875288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment?
    Grillo F; Valle L; Ferone D; Albertelli M; Brisigotti MP; Cittadini G; Vanoli A; Fiocca R; Mastracci L
    Endocrine; 2017 Sep; 57(3):494-502. PubMed ID: 28726181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system.
    Ezziddin S; Adler L; Sabet A; Pöppel TD; Grabellus F; Yüce A; Fischer HP; Simon B; Höller T; Biersack HJ; Nagarajah J
    J Nucl Med; 2014 Aug; 55(8):1260-6. PubMed ID: 24876204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated peptide receptor radiotherapy in multiple recurrences of a metastasized neuroendocrine tumor.
    Brogsitter C; Zöphel K; Folprecht G; Eisenhofer G; Kotzerke J
    Nuklearmedizin; 2017 Jun; 56(3):N19-N21. PubMed ID: 28358166
    [No Abstract]   [Full Text] [Related]  

  • 20. Grade Assignment by Ki-67 Proliferative Index, Mitotic Count, and Phosphohistone H3 Count in Surgically Resected Gastrointestinal and Pancreatic Neuroendocrine Tumors.
    Murphy CE; McCormick KA; Shankaran V; Reddi DM; Swanson PE; Upton MP; Papanicolau-Sengos A; Khor S; Westerhoff M
    Pancreas; 2017; 46(10):1359-1365. PubMed ID: 29040195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.